BioTech UCB

UCB Announces Availability Of Single-Injection Administration Option For BIMZELX - Quick Facts

January 16, 2025 — 07:19 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration options, each containing 160 mg of BIMZELX. The company noted that patients requiring a 320 mg dose of BIMZELX will have options for single-injection administration.

Camille Lee, Head of U.S. Immunology, UCB, said: "With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis, active psoriatic arthritis with coexistent moderate-to-severe plaque psoriasis, and moderate-to-severe hidradenitis suppurativa who receive a 320 mg dose of BIMZELX."

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned
UCB

Latest Articles
Data is currently not available